VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme

18th October 2024 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, met with the Regulatory Authority in the Netherlands, the Medicines Evaluation Board (MEB), on 17th October for a Scientific Advice meeting, following completion of the phase-1b study. During the meeting, the clinical protocol for the subsequent pivotal clinical trial to support the NG11-2 programme was discussed and a potential market approval roadmap for the programme was elucidated.

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“Following the successful completion of the NG11-2 phase-1b clinical trial, we plan to carry out sequential scientific advisory meetings with key regulatory authorities worldwide, so as to further clarify the market access strategy for this innovative programme. Our meeting with the MEB provided us with invaluable information to map out a clear development path and optimise the market access strategy in Europe.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk

Gary Bower, COO
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.